AnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Consensus Price Target from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $54.64.

Several brokerages have recently commented on ANAB. Guggenheim increased their price objective on AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a report on Monday. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of AnaptysBio in a research note on Wednesday, August 14th. JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the company an "overweight" rating in a research note on Wednesday, August 7th. Truist Financial lifted their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a research note on Thursday, August 15th. Finally, Wedbush reissued an "outperform" rating and issued a $42.00 target price on shares of AnaptysBio in a research report on Thursday, September 26th.

Insider Transactions at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the firm's stock in a transaction on Monday, September 16th. The stock was sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the sale, the chief financial officer now owns 4,744 shares of the company's stock, valued at $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total transaction of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares of the company's stock, valued at $189,333.04. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now owns 15,398 shares of the company's stock, valued at approximately $595,440.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 22,440 shares of company stock worth $892,936 in the last 90 days. Insiders own 33.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC purchased a new position in AnaptysBio during the 1st quarter valued at about $38,000. Values First Advisors Inc. purchased a new position in shares of AnaptysBio in the third quarter valued at approximately $49,000. nVerses Capital LLC grew its holdings in shares of AnaptysBio by 700.0% in the third quarter. nVerses Capital LLC now owns 1,600 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 1,400 shares in the last quarter. Headlands Technologies LLC increased its stake in AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock worth $89,000 after buying an additional 2,900 shares during the period. Finally, Virtu Financial LLC acquired a new stake in AnaptysBio during the 1st quarter worth approximately $222,000.

AnaptysBio Stock Down 1.1 %

Shares of NASDAQ ANAB traded down $0.40 during midday trading on Wednesday, reaching $34.75. 269,665 shares of the company's stock traded hands, compared to its average volume of 322,068. The company has a market cap of $949.34 million, a price-to-earnings ratio of -5.66 and a beta of -0.29. AnaptysBio has a one year low of $13.36 and a one year high of $41.31. The stock's 50 day simple moving average is $35.50 and its 200-day simple moving average is $29.63.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) earnings per share for the quarter, missing analysts' consensus estimates of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $10.97 million for the quarter, compared to analysts' expectations of $25.85 million. Equities analysts predict that AnaptysBio will post -6.84 EPS for the current fiscal year.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.